# Amber Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amber-bio

- Industry: Biotechnology
- Headquarters: San Francisco, US
- Website: www.amber.bio
- Total disclosed funding: $26M
- Latest round: Seed (Jun 7, 2023)
- Investors on record: 6

## About

Based in California, US, and founded in 2021, Amber Bio, Inc is a biotechnology company that provides gene editing approaches for intractable diseases. The company was co-founded by Jacob Borrajo (CEO) and Basem Al-Shayeb. In August 2023, the firm raised USD 26 million in Seed funding co-led by investors Andreessen Horowitz and Playground Ventures, with participation from other investors Eli Lilly & Company, Eli Lilly & Company, Pillar Companies, and Retinal Degeneration Fund.

The company develops a gene editing system to treat undruggable diseases. In order to treat diseases that were previously untreatable, the company provides gene editing techniques using multi-kilobase RNA writing. This facilitates the creation of treatments for every distinct mutation in the patient population.

The company plans to use the August 2023 funding to further develop its ribonucleic acid editing platform that empowers multi-kilobase edits, thereby facilitating the treatment of diseases with significant allelic diversity using a single drug.

## Funding rounds

- Seed, Jun 7, 2023, $26M — Hummingbird Ventures, Andreessen Horowitz, Eli Lilly & Company, Playground Ventures, Pillar, Retinal Degeneration Fund

## Investors

- Hummingbird Ventures (https://capitalatlas.ai/funds/hummingbird-ventures) — Seed
- Andreessen Horowitz (https://capitalatlas.ai/funds/andreessen-horowitz) — Seed
- Eli Lilly & Company — Seed
- Playground Ventures (https://capitalatlas.ai/funds/playground-ventures) — Seed
- Pillar (https://capitalatlas.ai/funds/pillar) — Seed
- Retinal Degeneration Fund (https://capitalatlas.ai/funds/retinal-degeneration-fund) — Seed